Therefore, inhibition of NEDD8 conjugation will lead to the stabilization of these oncogenic substrates, highlighting the necessity of developing CRL5-specific inhibitors for potential therapeutic management of GBM [31–36]. The gene discussed is NEDD8; the disease is glioblastoma.